Stefan Herget-Rosenthal, Kolja Stille, Klaus Albrecht, Hajo Findeisen, Martin Scharpenberg, Andreas Kribben
{"title":"Acute Kidney Injury in Very Old Patients - Incidence, Severity, Risk Factors and Short-Term Outcomes.","authors":"Stefan Herget-Rosenthal, Kolja Stille, Klaus Albrecht, Hajo Findeisen, Martin Scharpenberg, Andreas Kribben","doi":"10.1093/ndt/gfaf074","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and hypothesis: </strong>Although old age is a risk factor for acute kidney injury (AKI), data on AKI in individuals ≥80 years is limited. We aimed to provide data on AKI incidence, severity, and outcomes, to identify risk factors of AKI and 30-day mortality in those ≥80 years.</p><p><strong>Methods: </strong>Cohort study of 2132 patients admitted to hospital. AKI was defined and classified by extended KDIGO criteria to detect community-acquired AKI, frailty as a clinical frailty score ≥5. Primary endpoints were AKI and its stages, secondary endpoints 30-day mortality and major adverse kidney events (MAKE30), a composite of mortality, new renal replacement therapy, or serum creatinine values ≥200% of baseline, all at 30 days.</p><p><strong>Results: </strong>Median age was 86 years. AKI was frequent (35.3%) and predominately community-acquired (80.2%). The incidence rate of AKI rose with increasing age, reaching the maximum in patients 95 years old. 48.9% of AKI patients developed stage 1, while 27.0% and 24.1% reached stages 2 and 3, respectively. Frailty was identified as an independent AKI risk factor (adjusted odds ratio (aOR) 2.42 (95% confidence intervals (CI) 1.93-3.03). 30-day mortality rate was significantly higher in AKI compared to non-AKI patients (25.4 vs. 7.6%), 44.4% of AKI patients developed MAKE30. Among others, AKI and frailty were risk factors for 30-day mortality (aOR 3.02 (95% CI 2.25-4.07) and 1.53 (95% CI 1.16-2.02)), with frailty exceeding AKI in patients ≥90 years.</p><p><strong>Conclusions: </strong>AKI occurs frequently, increases with age, is severe and predominately community-acquired in individuals ≥80 years admitted to hospital. Frailty is a risk factor for AKI besides established factors. Very old patients with AKI more frequently died or developed a high rate of the composite endpoint MAKE30. AKI and frailty are risk factors for 30-day mortality. The effect of frailty on mortality exceeded that of AKI in nonagenarians.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrology Dialysis Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ndt/gfaf074","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"TRANSPLANTATION","Score":null,"Total":0}
引用次数: 0
Abstract
Background and hypothesis: Although old age is a risk factor for acute kidney injury (AKI), data on AKI in individuals ≥80 years is limited. We aimed to provide data on AKI incidence, severity, and outcomes, to identify risk factors of AKI and 30-day mortality in those ≥80 years.
Methods: Cohort study of 2132 patients admitted to hospital. AKI was defined and classified by extended KDIGO criteria to detect community-acquired AKI, frailty as a clinical frailty score ≥5. Primary endpoints were AKI and its stages, secondary endpoints 30-day mortality and major adverse kidney events (MAKE30), a composite of mortality, new renal replacement therapy, or serum creatinine values ≥200% of baseline, all at 30 days.
Results: Median age was 86 years. AKI was frequent (35.3%) and predominately community-acquired (80.2%). The incidence rate of AKI rose with increasing age, reaching the maximum in patients 95 years old. 48.9% of AKI patients developed stage 1, while 27.0% and 24.1% reached stages 2 and 3, respectively. Frailty was identified as an independent AKI risk factor (adjusted odds ratio (aOR) 2.42 (95% confidence intervals (CI) 1.93-3.03). 30-day mortality rate was significantly higher in AKI compared to non-AKI patients (25.4 vs. 7.6%), 44.4% of AKI patients developed MAKE30. Among others, AKI and frailty were risk factors for 30-day mortality (aOR 3.02 (95% CI 2.25-4.07) and 1.53 (95% CI 1.16-2.02)), with frailty exceeding AKI in patients ≥90 years.
Conclusions: AKI occurs frequently, increases with age, is severe and predominately community-acquired in individuals ≥80 years admitted to hospital. Frailty is a risk factor for AKI besides established factors. Very old patients with AKI more frequently died or developed a high rate of the composite endpoint MAKE30. AKI and frailty are risk factors for 30-day mortality. The effect of frailty on mortality exceeded that of AKI in nonagenarians.
背景与假设:虽然老年是急性肾损伤(AKI)的危险因素,但80岁以上人群AKI的数据有限。我们的目的是提供AKI发病率、严重程度和结局的数据,以确定≥80岁人群中AKI和30天死亡率的危险因素。方法:对2132例住院患者进行队列研究。AKI由扩展的KDIGO标准定义和分类,以检测社区获得性AKI,虚弱作为临床虚弱评分≥5。主要终点为AKI及其分期,次要终点为30天死亡率和主要肾脏不良事件(MAKE30),综合死亡率、新的肾脏替代治疗或血清肌酐值≥基线的200%,均为30天。结果:中位年龄86岁。AKI发生率较高(35.3%),主要为社区获得性(80.2%)。AKI的发病率随着年龄的增长而上升,在95岁时达到最大值。48.9%的AKI患者发展为1期,27.0%和24.1%分别发展为2期和3期。虚弱被确定为AKI的独立危险因素(调整优势比(aOR) 2.42(95%可信区间(CI) 1.93-3.03)。AKI患者的30天死亡率明显高于非AKI患者(25.4% vs. 7.6%), 44.4%的AKI患者发生MAKE30。其中,AKI和虚弱是30天死亡率的危险因素(aOR分别为3.02 (95% CI 2.25-4.07)和1.53 (95% CI 1.16-2.02),≥90岁的患者虚弱程度超过AKI。结论:AKI发生频繁,随年龄增长而增加,在≥80岁住院患者中较为严重,主要为社区获得性。除既定因素外,虚弱是AKI的危险因素。非常老的AKI患者更容易死亡或出现高比率的复合终点MAKE30。AKI和虚弱是30天死亡率的危险因素。在老年人群中,虚弱对死亡率的影响超过AKI。
期刊介绍:
Nephrology Dialysis Transplantation (ndt) is the leading nephrology journal in Europe and renowned worldwide, devoted to original clinical and laboratory research in nephrology, dialysis and transplantation. ndt is an official journal of the [ERA-EDTA](http://www.era-edta.org/) (European Renal Association-European Dialysis and Transplant Association). Published monthly, the journal provides an essential resource for researchers and clinicians throughout the world. All research articles in this journal have undergone peer review.
Print ISSN: 0931-0509.